SERVICIO ANDALUZ DE SALUD Patent applications |
Patent application number | Title | Published |
20150297613 | USE OF AGENTS THAT ALTER THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER - The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide NK1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor. The result of the alteration to the peritumoral environment is a reduction in the size of the tumor, the prevention of its development and, optionally, the induction of its disappearance. The invention also relates to pharmaceutical compositions containing said peritumoral-environment-altering agents, either alone or combined with at least one other active ingredient, for the treatment of cancer. | 10-22-2015 |
20150218635 | METHOD FOR OBTAINING DATA THAT CAN BE USED FOR THE DIAGNOSIS AND PROGNOSIS OF NEUROSENSORY HYPOACUSIS - A method for obtaining useful data for the determination of an individual's risk of suffering from severe sensorineural hearing loss, preferably in Ménière's disease, primers useful in the determination and kit comprising same. | 08-06-2015 |
20150087880 | USE OF A COMPOSITION COMPRISING A POLY-ORGANOSILOXANE - A composition based on a poly-organosiloxane which is suitable for its use as a bolus in radiotherapy treatments. Other possible uses of this composition are the production of an immobilizing mask for radio surgery or cranial stereotaxy treatments and the production of an intraoral depressor. | 03-26-2015 |
20140148439 | USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME - The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome. | 05-29-2014 |
20140045205 | GLUTAMYL AMINOPEPTIDASE AS A MARKER OF RENAL DAMAGE - The present invention relates to a method and a kit for the diagnosis and/or prognosis of kidney injury comprising analysing a sample obtained from a patient and determining the activity of at least one aminopeptidase selected from aspartyl aminopeptidase, glutamyl aminopeptidase, alanyl aminopeptidase and leucyl-cystinyl aminopeptidase. | 02-13-2014 |
20130280259 | USE OF ANTIBODIES AGAINST NK1, NK2 AND/OR NK3 RECEPTORS IN CANCER TREATMENT - The object of this invention is the use of an antibody or a fragment thereof specific against NK1, NK2 and/or NK3 receptors of cells, for the manufacture of a medicament for the therapeutic management of human cancer, by direct administration to a mammal, including humans, by inducing cell death or apoptosis of tumour cells, modification of peritumoural microenvironment (consisting of stromal cells, stromal matrix, and intra and peritumoural vascularisation) and/or inflammatory and/or immune response around the tumour. In particular, in the case of melanoma, carcinoma (specially, breast carcinoma, lung, digestive system, prostate, cervix, endometrium, ovary and bladder), leukaemia, lymphomas, neoplasms, such as neuroblastoma and sarcoma, such as osteosarcoma. | 10-24-2013 |
20130022582 | MULTIPOTENT NESTIN-POSITIVE CELLS - The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal. | 01-24-2013 |
20120141435 | USE OF OLIVE LEAF EXTRACTS IN A PHARMACEUTICAL COMPOSITION FOR INDUCING ANGIOGENESIS AND VASCULOGENESIS - The invention relates to the use of olive leaf extracts for producing a pharmaceutical composition capable of inducing angiogenesis and vascularization. In general, the composition can be used for therapeutic applications in order to promote the differentiation of stem cells into endothelial progenitor cells (EPCs) and/or mature endothelial cells, as well as to induce the vessel formation from said endothelial cells. The vascularization-inducing angiogenic composition of the invention is intended for, inter alia, cardiovascular disease, ischemic processes in general, ulcers, and wound healing in both human and veterinary medicine. | 06-07-2012 |